BioNTech has been granted a patent for imidazoquinoline derivatives that act as toll-like receptor agonists, specifically targeting TLR7 and promoting the induction of certain cytokines. The compounds are used in pharmaceutical compositions. GlobalData’s report on BioNTech gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on BioNTech, Personalized cancer vaccines was a key innovation area identified from patents. BioNTech's grant share as of May 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent (Publication Number: US11987569B2) discloses a compound represented by a specific chemical formula (I) and its various derivatives, solvates, and salts. The compound includes different substituents such as ethyl, methyl, propyl, butyl, methoxyethyl, and ethylaminomethyl, which can be further modified with groups like -OH and halogen. These compounds are intended for use in pharmaceutical compositions along with suitable excipients for the treatment of proliferative diseases, including cancer.
Furthermore, the patent claims cover methods of treating proliferative diseases, particularly cancer, by administering the disclosed compounds or pharmaceutical compositions to individuals in need. The treatment aims at achieving complete or partial healing, alleviation, or halting the progression of the proliferative disease. The compounds mentioned in the claims exhibit specific structural features, including the presence of unsubstituted 1,1-dioxothietan-3-yl and variations in R1 and R2 groups, which contribute to their therapeutic potential. The patent also specifies the range of n in the compound's structure and provides examples of specific compounds and their derivatives that fall under the scope of the invention.
To know more about GlobalData’s detailed insights on BioNTech, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
